These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20706133)

  • 41. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.
    Ziyadeh FN; Wolf G
    Curr Diabetes Rev; 2008 Feb; 4(1):39-45. PubMed ID: 18220694
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Upregulation of podocyte-secreted angiopoietin-like-4 in diabetic nephropathy.
    Ma J; Chen X; Li JS; Peng L; Wei SY; Zhao SL; Li T; Zhu D; He YX; Wei QJ; Li B
    Endocrine; 2015 Jun; 49(2):373-84. PubMed ID: 25424436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.
    Naito T; Ma LJ; Yang H; Zuo Y; Tang Y; Han JY; Kon V; Fogo AB
    Am J Physiol Renal Physiol; 2010 Mar; 298(3):F683-91. PubMed ID: 20042458
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calpastatin prevents Angiotensin II-mediated podocyte injury through maintenance of autophagy.
    Bensaada I; Robin B; Perez J; Salemkour Y; Chipont A; Camus M; Lemoine M; Guyonnet L; Lazareth H; Letavernier E; Hénique C; Tharaux PL; Lenoir O
    Kidney Int; 2021 Jul; 100(1):90-106. PubMed ID: 33675847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simultaneous angiotensin receptor blockade and glucagon-like peptide-1 receptor activation ameliorate albuminuria in obese insulin-resistant rats.
    Rodriguez R; Escobedo B; Lee AY; Thorwald M; Godoy-Lugo JA; Nakano D; Nishiyama A; Parkes DG; Ortiz RM
    Clin Exp Pharmacol Physiol; 2020 Mar; 47(3):422-431. PubMed ID: 31675433
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of Ceramide Accumulation in Podocytes by Myriocin Prevents Diabetic Nephropathy.
    Woo CY; Baek JY; Kim AR; Hong CH; Yoon JE; Kim HS; Yoo HJ; Park TS; Kc R; Lee KU; Koh EH
    Diabetes Metab J; 2020 Aug; 44(4):581-591. PubMed ID: 31701696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPKα activity.
    Lu J; Chen PP; Zhang JX; Li XQ; Wang GH; Yuan BY; Huang SJ; Liu XQ; Jiang TT; Wang MY; Liu WT; Ruan XZ; Liu BC; Ma KL
    Theranostics; 2021; 11(10):4728-4742. PubMed ID: 33754024
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.
    Whaley-Connell A; Nistala R; Habibi J; Hayden MR; Schneider RI; Johnson MS; Tilmon R; Rehmer N; Ferrario CM; Sowers JR
    Am J Physiol Renal Physiol; 2010 Mar; 298(3):F655-61. PubMed ID: 20007350
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Downregulation of the antioxidant protein peroxiredoxin 2 contributes to angiotensin II-mediated podocyte apoptosis.
    Hsu HH; Hoffmann S; Di Marco GS; Endlich N; Peter-Katalinić J; Weide T; Pavenstädt H
    Kidney Int; 2011 Nov; 80(9):959-969. PubMed ID: 21814176
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells.
    Ebefors K; Wiener RJ; Yu L; Azeloglu EU; Yi Z; Jia F; Zhang W; Baron MH; He JC; Haraldsson B; Daehn I
    Kidney Int; 2019 Oct; 96(4):957-970. PubMed ID: 31402170
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nephron deficit and low podocyte density increase risk of albuminuria and glomerulosclerosis in a model of diabetes.
    Gazzard SE; van der Wolde J; Haruhara K; Bertram JF; Cullen-McEwen LA
    Physiol Rep; 2023 Jan; 11(2):e15579. PubMed ID: 36695822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
    Davis BJ; Cao Z; de Gasparo M; Kawachi H; Cooper ME; Allen TJ
    J Hypertens; 2003 Jan; 21(1):209-16. PubMed ID: 12544453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An adjustment in BMP4 function represents a treatment for diabetic nephropathy and podocyte injury.
    Fujita Y; Tominaga T; Abe H; Kangawa Y; Fukushima N; Ueda O; Jishage KI; Kishi S; Murakami T; Saga Y; Kanwar YS; Nagai K; Doi T
    Sci Rep; 2018 Aug; 8(1):13011. PubMed ID: 30158674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition.
    Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B
    J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Loss of sulfated carbohydrate from the glomerular podocyte as a cause of albuminuria in experimental diabetic rats: ultrastructural histochemical study.
    Ina K; Kitamura H; Nakamura M; Ono J; Takaki R
    J Diabet Complications; 1991; 5(2-3):173-5. PubMed ID: 1770036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.
    Jourdan T; Szanda G; Rosenberg AZ; Tam J; Earley BJ; Godlewski G; Cinar R; Liu Z; Liu J; Ju C; Pacher P; Kunos G
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5420-8. PubMed ID: 25422468
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
    Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
    Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mangiferin prevents diabetic nephropathy progression and protects podocyte function via autophagy in diabetic rat glomeruli.
    Wang X; Gao L; Lin H; Song J; Wang J; Yin Y; Zhao J; Xu X; Li Z; Li L
    Eur J Pharmacol; 2018 Apr; 824():170-178. PubMed ID: 29444469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. C3a receptor blockade protects podocytes from injury in diabetic nephropathy.
    Morigi M; Perico L; Corna D; Locatelli M; Cassis P; Carminati CE; Bolognini S; Zoja C; Remuzzi G; Benigni A; Buelli S
    JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deficiency of the Angiotensinase Aminopeptidase A Increases Susceptibility to Glomerular Injury.
    Velez JCQ; Arif E; Rodgers J; Hicks MP; Arthur JM; Nihalani D; Bruner ET; Budisavljevic MN; Atkinson C; Fitzgibbon WR; Janech MG
    J Am Soc Nephrol; 2017 Jul; 28(7):2119-2132. PubMed ID: 28202497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.